Skip to Main Content

340B Drug Pricing Program: Rebate Model Considerations

Share via LinkedIn
Share via Twitter
Share via Facebook
Date: 25 March 2026
Triage
By: Gabriel T. Scott, Mark O. Ogunsusi, Amanda Smith

In this episode, Gabriel Scott, Mark Ogunsusi, and Amanda Smith take a focused look at the 340B Drug Pricing Program, with particular attention to recent developments related to proposals for a 340B rebate model. They discuss why stakeholders may support or oppose a rebate based approach to 340B pricing and highlight key considerations relating to such a model.

Gabriel T. Scott
Gabriel T. Scott
Research Triangle Park
Mark O. Ogunsusi
Mark O. Ogunsusi
Washington, DC
Amanda Smith
Amanda Smith
Washington, DC
Find more items tagged as: Digital Health, Healthcare, Healthcare and FDA, Healthcare Payor-Provider Disputes (US), Healthcare Transactions, Hospitals and Health Systems, Policy and Regulatory
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel